Haemostasis Section, Biotherapeutics Division, National Institute for Biological Standards and Control, South Mimms, UK.
Biostatistics Section, National Institute for Biological Standards and Control, South Mimms, UK.
J Thromb Haemost. 2021 Mar;19(3):852-858. doi: 10.1111/jth.15207.
The calibration of thrombin products relies on the World Health Organization (WHO) 2nd International Standard (IS) for Thrombin (01/580) which defines the international unit (IU) for thrombin potency. With stocks of the 2nd IS (01/580) running low, an international collaborative study was organized to calibrate a replacement. Twenty laboratories from 13 countries took part in the study and measured the potency of two candidate replacement standards (coded 01/578 and 19/188) relative to the 2nd IS. In total, 111 valid assays were returned, which were a combination of plasma/fibrinogen clotting assays and chromogenic assays. Variation between and within laboratories was low, with inter- and intra-laboratory geometric coefficient of variation (GCV) generally <5% for all assay methods and substrates. For 01/578, potency estimates by clotting assays (101.1 IU/ampoule) were significantly lower than estimates by chromogenic assays (111.5 IU/ampoule). Mean potency estimates for 19/188 were 90.4 IU/ampoule by clotting assay and 88.1 IU/ampoule by chromogenic assay, which was not a statistically significant difference. The close ratio between clotting and chromogenic assay potency estimates for 19/188 suggests it has a higher α-thrombin content than 01/578 and is equivalent to the current IS (01/580). Accelerated degradation studies predicted excellent long-term stability profiles for preparations 01/580, 01/578, and 19/188. Based on the results of this study, the WHO Expert Committee on Biological Standardization established 19/188 as the 3rd IS for Thrombin with a potency of 90 IU/ampoule in August 2020.
凝血酶产品的校准依赖于世界卫生组织(WHO)的第 2 国际标准(IS)凝血酶(01/580),该标准定义了凝血酶效价的国际单位(IU)。随着第 2 国际标准(01/580)库存的减少,组织了一项国际协作研究来校准替代品。来自 13 个国家的 20 个实验室参与了这项研究,并相对于第 2 国际标准(IS)测量了两种候选替代标准(编码为 01/578 和 19/188)的效价。总共返回了 111 份有效测定值,这些测定值是血浆/纤维蛋白原凝结测定和显色测定的组合。实验室之间和实验室内部的差异很小,所有测定方法和基质的实验室间和实验室内几何变异系数(GCV)通常均<5%。对于 01/578,凝结测定(101.1 IU/安瓿)的效价估计值明显低于显色测定(111.5 IU/安瓿)的效价估计值。19/188 的平均效价估计值通过凝结测定为 90.4 IU/安瓿,通过显色测定为 88.1 IU/安瓿,这没有统计学上的显着差异。19/188 的凝结和显色测定效价估计值之间的接近比值表明其α-凝血酶含量高于 01/578,并且与当前的 IS(01/580)等效。加速降解研究预测 01/580、01/578 和 19/188 制剂具有极好的长期稳定性。基于这项研究的结果,世界卫生组织生物标准化专家委员会于 2020 年 8 月将 19/188 确立为凝血酶的第 3 个 IS,效价为 90 IU/安瓿。